Neptinib Di-P-methylbenzenesulfonate

二甲苯磺酸萘普替尼

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameNeptinib Di-P-methylbenzenesulfonate
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor protein-tyrosine kinase erbB-4
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Neptunus Pharmaceutical Research Institute Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenzhen Neptunus Bioengineering Co LtdShenzhen Neptunus Pharmaceutical Research Institute Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A